Innovent Biologics - IVBXF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.28
+0 (0.00%)

This chart shows the closing price for IVBXF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Innovent Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IVBXF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IVBXF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Innovent Biologics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.28.

This chart shows the closing price for IVBXF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Innovent Biologics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/2/2023CitigroupInitiated CoverageBuy
5/12/2022Daiwa Capital MarketsUpgradeUnderperform ➝ Hold
2/7/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy
11/3/2020Daiwa Capital MarketsInitiated CoverageBuy
7/8/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
(Data available from 4/21/2019 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/23/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/22/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/21/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/21/2024

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Innovent Biologics logo
Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Read More

Today's Range

Now: $4.28
Low: $4.28
High: $4.28

50 Day Range

MA: $4.93
Low: $4.28
High: $5.48

52 Week Range

Now: $4.28
Low: $3.55
High: $6.41

Volume

N/A

Average Volume

227,844 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Innovent Biologics?

The following Wall Street research analysts have issued research reports on Innovent Biologics in the last year: Citigroup Inc..
View the latest analyst ratings for IVBXF.

What is the current price target for Innovent Biologics?

0 Wall Street analysts have set twelve-month price targets for Innovent Biologics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Innovent Biologics in the next year.
View the latest price targets for IVBXF.

What is the current consensus analyst rating for Innovent Biologics?

Innovent Biologics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IVBXF will outperform the market and that investors should add to their positions of Innovent Biologics.
View the latest ratings for IVBXF.

What other companies compete with Innovent Biologics?

Other companies that are similar to Innovent Biologics include 180 Life Sciences, 3SBio, 60 Degrees Pharmaceuticals, Abcam and Adocia. Learn More about companies similar to Innovent Biologics.

How do I contact Innovent Biologics' investor relations team?

Innovent Biologics' physical mailing address is 168 Dongping Street, Suzhou, Jiangsu 215123. The company's listed phone number is 86-512-6956-6088. The official website for Innovent Biologics is www.innoventbio.com. Learn More about contacing Innovent Biologics investor relations.